S&P 500 headed for sixth straight decline as J&J advanced two products

In a November 19, 2026, afternoon update, CNBC’s Investing Club reported that the S&P 500 was on pace for its sixth consecutive decline. The index had fallen roughly 7% from its October 6 record close of 7,818.93. The update linked Thursday’s weakness in AI-related stocks to a reversal in Anthropic shares: they opened at $111.50, up 34% from their $83 IPO price, before falling below $100.

Johnson & Johnson, meanwhile, announced that Memorial Hermann-Texas Medical Center in Houston would be the first hospital to commercially install its Ottava robotic surgical system. The hospital participated in Ottava’s clinical trials. In July, the FDA authorized the system for use in 10 upper-abdominal general surgery procedures. J&J is seeking to compete in a market long dominated by Intuitive Surgical, though the Investing Club characterized Ottava as a longer-term growth prospect rather than an immediate driver of results.

J&J also submitted its antipsychotic drug Caplyta to the FDA for approval to treat manic episodes associated with bipolar I disorder. According to the update, two late-stage studies found that Caplyta reduced manic symptoms compared with a placebo as early as day three, with improvement sustained through week three. The proposed use has not been approved; if cleared, it would be Caplyta’s fifth approved use in adults.

Caplyta’s third-quarter revenue rose 66% from a year earlier to $398 million, and its 2026 sales had exceeded $1 billion, the update said. Despite the product news, J&J shares were down about 7% from their record close the preceding Friday.

Further reading